Proposal for risk-based scientific approach on full and partial validation for general changes in bioanalytical...

Area of Science:

• Pharmaceutical Analysis
• Analytical Chemistry
• Drug Development

Background:

• Regulatory guidelines from US FDA, EMA, and MHLW detail full bioanalytical method validation parameters.
• These guidelines lack specific details for partial validation, creating ambiguity in the industry.

Purpose of the Study:

• To provide detailed perspectives and recommendations for partial bioanalytical method validation.
• To address the need for clearer guidance based on risk assessment and practical experience.

Main Methods:

• Analysis of survey data on bioanalysis of small molecules using LC-MS/MS in Japan.
• Discussions and consensus building within Japan Bioanalysis Forum (JBF) working groups (2012-2014).
• Risk-based assessment of validation parameters for small molecule bioanalysis.

Main Results:

• Identified key considerations and potential changes for both full and partial bioanalytical method validation.
• Developed practical recommendations informed by pharmaceutical companies and contract research organizations.
• Highlighted the importance of risk assessment in defining validation strategies.

Conclusions:

• The manuscript offers valuable insights for optimizing bioanalytical method validation processes.
• Recommendations aim to enhance the efficiency and regulatory compliance of partial validation.
• The findings contribute to harmonizing validation practices in the pharmaceutical industry.